Phlox Therapeutics is at the forefront of developing innovative gene therapies aimed at addressing genetic heart diseases, particularly cardiomyopathies. The company focuses on creating precision genetic medicines that target the underlying causes of these conditions, rather than merely alleviating symptoms. Their approach is designed to provide long-term benefits for patients suffering from genetic heart diseases, which are a leading cause of mortality worldwide. By leveraging advanced RNA-based therapies, Phlox aims to transform the treatment landscape for these conditions, offering hope where current standard care falls short.

In collaboration with Solid Biosciences, Phlox Therapeutics is enhancing its capabilities in developing RNA therapies specifically for rare genetic cardiomyopathies, including laminopathies. This strategic partnership combines Solid Biosciences' expertise in vector biology and drug development with Phlox's specialization in RNA therapeutics. Together, they aim to accelerate the development of novel therapies for severe forms of genetic dilated cardiomyopathy, addressing significant unmet medical needs. Through these efforts, Phlox Therapeutics is committed to pioneering solutions that could potentially cure genetic heart diseases and improve the quality of life for affected patients and their families.

Netherlands

Phlox Therapeutics pioneers gene therapy to alleviate and cure cardiomyopathies. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short by leveraging RNA-based strategies to reduce the negative effects caused by genetic mutations. 

Phlox Therapeutics

Company Details